Search ABBV
AbbVie Inc.
NYSE · CIK 1551152
Last close262.82
Daily change+2.89 (1.11%)
10 Years gain+395.41%
Dividends TTM6.83 (+5.56%)
Dividend yield2.63%
Fundamental Analysis
ABBV · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
49.4Momentum
n/aAcceleration
n/aConfidence
78.0Annual Revenue15
Quarterly Revenue69
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.4 / 25
Quality17.6 / 25
Capital Efficiency12.5 / 20
Balance Sheet2.7 / 15
Shareholder Economics8.8 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.5468 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM10.39%OK
Revenue CAGR 3Y1.75%OK
Gross Margin71.48%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $61.16B | $42.96B | $15.08B | $19.03B | $17.82B | 70.24% | 24.65% | 29.13% | 16.25% | 1.77B |
| 2025 FY Dec 31, 2024 | $56.33B | $39.43B | $9.14B | $18.81B | $17.83B | 69.99% | 16.22% | 31.65% | 12.74% | 1.77B |
| 2025 FY Dec 31, 2023 | $54.32B | $33.90B | $12.76B | $22.84B | $22.06B | 62.42% | 23.49% | 40.62% | 15.55% | 1.77B |
| 2024 FY Dec 31, 2022 | $58.05B | $40.64B | $18.12B | $24.94B | $24.25B | 70% | 31.21% | 41.77% | 20.86% | 1.78B |
| 2023 FY Dec 31, 2021 | $56.20B | $38.75B | $17.92B | $22.78B | $21.99B | 68.96% | 31.89% | 39.13% | 18.63% | 1.78B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $64.39B | sum latest 4 fiscal quarters Revenue | OK | 0001551152-25-000049, 0001551152-26-000008 |
| Revenue Growth TTM | 10.39% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001551152-25-000049, 0001551152-26-000008 |
| Revenue CAGR 3Y | 1.75% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001551152-26-000008 |
| Revenue CAGR 5Y | 5.95% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001551152-26-000008 |
| Gross Profit CAGR 3Y | 1.86% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001551152-26-000008 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 71.48% | Gross Profit / Revenue | OK | 0001551152-25-000049, 0001551152-26-000008 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001551152-26-000026 |
| Current Ratio | 0.81x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $36.36 | Revenue / Diluted Shares | OK | 0001551152-25-000049, 0001551152-26-000008 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | 275.84% | Cash dividends paid / Net income | OK | 0001551152-26-000008 |
| Diluted EPS TTM | $3.56 | Net income TTM / Diluted shares | OK | 0001551152-25-000049, 0001551152-26-000008 |